Date: 2013-05-21
Type of information: Company acquisition
Acquired company: Xellia Pharmaceuticals (Norway)
Acquiring company: Novo A/S (Denmark)
Amount: $ 700 million (€ 543 million)
Terms:
- Novo A/S , the holding company of the Novo Group, has purchased all shares of Xellia Pharmaceuticals for approximately $ 700 million (€ 543 million) from 3i and other current shareholders. As a consequence of the transaction, Xellia will revert to Danish ownership with headquartersin Copenhagen, Denmark. Closing of the transaction will be subject to relevant competition law approvals, and is expected to take place during the third quarter of 2013.
Details:
- Xellia Pharmaceuticals is a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, with over 100 years of experience and expertise in the supply of fermented and semi-synthetic finished dose products and active pharmaceutical ingredients for life-saving therapies against serious infections. The Company has growing sales in more than 70 countries to over 700 customers across the healthcare industry and for the financial year ending December 31 2012 generated revenues of US$220 million. Currently headquartered in Oslo, Norway, Xellia has global facilities including operational and manufacturing capabilities in Denmark, Hungary and China, and currently employs 900 people, of which 400 are working in Denmark. Xellia is a leading supplier of Vancomycin and Colistimethate Sodium (CMS) which together combat life-threatening, multi-drug resistant (MDR) bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry(Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.
Related: Infectious diseases
Is general: Yes
